Odysight.Ai Inc. (ODYS) - 10-K Filing Summary
Business Context and Reporting Period
Company: Odysight.Ai Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Listing Status: Began trading on Nasdaq Capital Market (Symbol: ODYS) on February 11, 2025, following an uplisting from OTCQB.
Business Overview: Odysight.Ai develops the TruVision solution, an AI-driven, vision-based sensor platform for Predictive Maintenance (PdM) and Condition-Based Monitoring (CBM). The technology monitors critical safety components in hard-to-reach locations across aerospace, defense, medical, and industrial sectors. Key customers include NASA, the Israeli Air Force, Safran Aircraft Engines, and a Fortune 500 medical company.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (USD) | 2023 (USD) |
|---|---|---|
| Revenues | $3,964,000 | $3,033,000 |
| Gross Profit | $1,157,000 | $509,000 |
| Gross Margin | 29.2% | 16.8% |
| Operating Loss | $(12,507,000) | $(10,633,000) |
| Net Loss | $(11,767,000) | $(9,445,000) |
| Cash & Equivalents (End of Period) | $18,164,000 | $8,945,000 |
| Accumulated Deficit | $(45,974,000) | $(34,207,000) |
| Backlog (Dec 31, 2024) | ~$15,000,000 | ~$2,600,000 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 31% year-over-year, driven by expanded sales of vision-based platform solutions in the PdM and CBM markets.
- Margin Expansion: Gross profit increased 127% to $1.16 million, with gross margin improving from 16.8% to 29.2%.
- Expense Increases: Operating expenses rose significantly. Research and Development (R&D) increased 23% to $6.9 million due to new product development and hiring. General and Administrative (G&A) expenses increased 26% to $5.6 million, attributed to professional services, new executive recruitment (CFO), and stock-based compensation.
- Backlog Surge: Backlog grew substantially from $2.6 million in 2023 to approximately $15 million in 2024, reflecting major contracts with government and defense clients.
- Liquidity Position: Cash and cash equivalents more than doubled to $18.2 million, bolstered by a private placement in July 2024 and a public offering in February 2025 (subsequent event).
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects expenses to increase as the company scales operations and invests in R&D for Industry 4.0 applications. The company believes current cash resources will fund operations for at least the next 12 months.
- Customer Concentration Risk: In 2024, four customers accounted for approximately 99% of total revenue. The company explicitly states it does not expect a purchase order from its primary Fortune 500 medical customer for 2025, or if received, it may be substantially lower than 2024 levels. This poses a significant risk to near-term revenue stability.
- Geopolitical Risk: Operations are headquartered in Israel. The filing details the impact of the ongoing war, including employee reserve duty call-ups and potential delays in client transactions, though management asserts no material adverse effect to date.
- Regulatory Constraints: The company is subject to the Israeli Innovation Authority (IIA) regulations, which restrict the transfer of know-how and manufacturing outside of Israel without approval and potential redemption fees.
- Subsequent Event: In February 2025, the company completed a public offering of 3,653,124 shares at $6.50 per share, generating gross proceeds of approximately $23.7 million.
Key Facts for Investor Verification
- Revenue Dependency: Verify the status of the 2025 purchase order from the Fortune 500 medical customer, which historically drove the majority of revenue.
- Backlog Realization: Assess the timeline and certainty of converting the $15 million backlog into recognized revenue, given the long sales cycles in defense and aerospace.
- Path to Profitability: Review the burn rate against the $18.2 million cash balance to determine the runway before additional capital raises are required.
- Geopolitical Exposure: Monitor the impact of the conflict in Israel on supply chains, employee availability, and international customer sentiment.
- IIA Restrictions: Understand the limitations on transferring technology or manufacturing outside Israel, which could impact M&A or expansion strategies.